{"abstract":"The National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Memorial Sloan Kettering Cancer Center, (\"MSKCC\"), a non-profit research center located in New York, in its rights to the inventions and patents listed in the SUPPLEMENTARY INFORMATION section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/03/30/2021-06474.html","cfr_references":[],"citation":"86 FR 16602","comment_url":null,"comments_close_on":"2021-04-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center April 14, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-06474","effective_on":null,"end_page":16602,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/03/30/2021-06474.xml","html_url":"https://www.federalregister.gov/documents/2021/03/30/2021-06474/prospective-grant-of-exclusive-patent-license-chimeric-antigen-receptors-targeting-cd56","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-06474?publication_date=2021-03-30","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-03-30/2021-06474/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":168,"last_updated":"2026-06-26 18:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-03-30/pdf/2021-06474.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-06474.pdf?1617021921","publication_date":"2021-03-30","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/03/30/2021-06474.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:32:20Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":16602,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Chimeric Antigen Receptors Targeting CD56","toc_doc":"Chimeric Antigen Receptors Targeting CD56","toc_subject":"Prospective Grant of Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}